psalexa
logo

Androgenic Alopecia Therapeutics Pipeline Analysis 2017

Androgenic Alopecia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other

Published: November 2017
Report Code: LS11169
Available Format:
Pages: 112

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1. Research Objectives

1.2. Definition

1.3. Research Scope

1.3.1. Pipeline Analysis by Phase

1.3.2. Pipeline Analysis by Route of Administration

1.3.3. Pipeline Analysis by Molecule Type

1.3.4. Pipeline Analysis by Target

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By industry participants

2.2.1.2. By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1. Androgenic Alopecia Overview

4.1.1. Signs and Symptoms

4.1.2. Pathophysiology

4.1.3. Diagnosis

4.1.4. Treatment

4.1.5. Epidemiology

4.2. Key Drivers

4.3. Key Barriers

4.4. Androgenic Alopecia Therapeutics Pipeline Analysis

4.4.1. Pipeline Analysis by Phase

4.4.2. Pipeline Analysis by Route of Administration

4.4.3. Pipeline Analysis by Molecule Type

4.4.4. Pipeline Analysis by Target

4.4.5. Pipeline Analysis by Company

Chapter 5. Androgenic Alopecia Therapeutics Pipeline Analysis by Phase (2017)

5.1. Phase III: Drug Profiles

5.1.1. P-3074

5.1.1.1. Pre-Clinical Studies

5.1.1.2. Clinical Trials

5.1.1.3. Clinical Results

5.1.1.4. Strategic Developments

5.1.1.5. Designations

5.1.1.6. Grants

5.1.1.7. Patents

5.1.1.8. Technology

5.2. Phase II: Drug Profiles

5.2.1. SM04554

5.2.1.1. Pre-Clinical Studies

5.2.1.2. Clinical Trials

5.2.1.3. Clinical Results

5.2.1.4. Strategic Developments

5.2.1.5. Designations

5.2.1.6. Grants

5.2.1.7. Patents

5.2.1.8. Technology

5.3. Phase I: Drug Profiles

5.3.1. RCH-01

5.3.1.1. Pre-Clinical Studies

5.3.1.2. Clinical Trials

5.3.1.3. Clinical Results

5.3.1.4. Strategic Developments

5.3.1.5. Designations

5.3.1.6. Grants

5.3.1.7. Patents

5.3.1.8. Technology

5.4. Pre-Clinical: Drug Profiles

5.4.1. BMD-1141

5.4.1.1. Pre-Clinical Studies

5.4.1.2. Strategic Developments

5.4.1.3. Designations

5.4.1.4. Grants

5.4.1.5. Patents

5.4.1.6. Technology

5.5. Discovery: Drug Profiles

5.5.1. Small Molecules to Inhibit JAK to Treat Androgenetic Alopecia

5.5.1.1. Strategic Developments

5.5.1.2. Designations

5.5.1.3. Grants

5.5.1.4. Patents

5.5.1.5. Technology

5.6. Discontinued: Drug Profiles

5.6.1. Discontinued Drugs

5.6.1.1. Pre-Clinical Studies

5.6.1.2. Clinical Trials

5.6.1.3. Clinical Results

5.6.1.4. Strategic Developments

5.6.1.5. Designations

5.6.1.6. Grants

5.6.1.7. Patents

5.6.1.8. Technology

Chapter 6. Clinical Trials Analysis

6.1. Clinical Trials Analysis by Region

6.2. Clinical Trials Analysis by Trial Status

Chapter 7. Competitive Landscape Analysis

7.1. Key Players Benchmarking for Androgenic Alopecia Therapeutics Pipeline

7.2. SWOT Analysis of Androgenic Alopecia Therapeutics Pipeline

Chapter 8. Company Profiles

8.1. Merck & Co., Inc.

8.1.1. Business Overview

8.1.2. Product and Service Offerings

8.2. Allergan plc

8.2.1. Business Overview

8.2.2. Product and Service Offerings

8.3. Almirall, S.A.

8.3.1. Business Overview

8.3.2. Product and Service Offerings

8.4. RepliCel Life Sciences Inc.

8.4.1. Business Overview

8.4.2. Product and Service Offerings

8.5. RiverTown Therapeutics, Inc.

8.5.1. Business Overview

8.5.2. Product and Service Offerings

8.6. Company 6

8.6.1. Business Overview

8.6.2. Product and Service Offerings

8.7. Company 7

8.7.1. Business Overview

8.7.2. Product and Service Offerings

8.8. Company 8

8.8.1. Business Overview

8.8.2. Product and Service Offerings

Chapter 9. Appendix

9.1. Abbreviations

9.2. Related Reports

Note: Certain sections of the above table of contents would vary according to the availability of information.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry